| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥238.8B | ¥189.1B | +26.3% |
| Operating Income | ¥59.0B | ¥52.6B | +12.3% |
| Ordinary Income | ¥70.9B | ¥65.8B | +7.7% |
| Net Income | ¥42.6B | ¥43.3B | -1.7% |
| ROE | 11.8% | 13.7% | - |
FY2025 (February 2025 - January 2026) consolidated results showed Revenue of 238.8B yen (YoY +26.3%), Operating Income of 59.0B yen (+12.3%), Ordinary Income of 70.9B yen (+7.7%), and Net Income of 42.6B yen (-1.7%, Net Income Attributable to Owners +11.1% at 55.15B yen). The company achieved revenue growth for consecutive periods driven by strong demand from semiconductor manufacturing customers in China and Taiwan. Operating margin remained robust at 24.7%, though the growth rate of operating income (+12.3%) lagged behind revenue expansion, indicating margin compression pressures. The gap between ordinary income and net income primarily stems from differences in reporting methodology, with equity method investment income of 12.8B yen contributing significantly to profitability.
Revenue expanded by 49.78B yen YoY to 238.8B yen, driven primarily by geographic expansion in semiconductor-related demand. Regional revenue composition shows China contributing 81.2B yen (+15.9% YoY), Taiwan 80.6B yen (+34.4% YoY), Japan 45.0B yen (+15.7% YoY), and Korea 22.1B yen (+43.1% YoY). Top three customers (TOPCO Scientific, Air Liquide Japan, and Changxin Xinqiao Memory Technologies) collectively generated approximately 112.4B yen in revenue, representing significant customer concentration. The company operates in a single business segment of high-purity chemical compounds for semiconductor manufacturing, eliminating cross-segment dynamics but creating concentrated industry exposure.
From a profitability perspective, gross profit increased to 90.2B yen with a gross margin of 37.8% (vs prior period gross profit of 80.1B yen at 42.4% margin), showing 5.4pt margin compression attributable to product mix shifts and cost structure changes including increased raw materials inventory from 32.9B yen to 41.4B yen. SG&A expenses rose to 31.2B yen (13.1% of revenue) from 27.6B yen (14.6% of revenue), demonstrating operating leverage improvement with SG&A ratio declining 1.5pt despite absolute increases. Operating income reached 59.0B yen with an operating margin of 24.7%, down 2.8pt from prior year's 27.8%, reflecting the gross margin compression flowing through to operating results.
Ordinary income of 70.9B yen exceeded operating income by 11.9B yen due to non-operating items, primarily equity method investment income of 12.8B yen (vs 13.1B yen prior year). This equity method contribution represents approximately 5.4% of revenue and significantly enhances profitability metrics. Interest expense remained minimal at 0.3B yen despite long-term debt increasing from 7.2B yen to 30.8B yen, indicating favorable borrowing terms. The gap between ordinary income (70.9B yen) and net income attributable to owners (55.15B yen) of 15.75B yen is primarily explained by income tax expense of 15.7B yen and minority interests, representing an effective tax rate of approximately 22.2% on pre-tax profit of 70.9B yen.
This represents a revenue up, profit up pattern, though with notable margin compression requiring attention to cost management and pricing power sustainability.
The company operates a single business segment of high-purity chemical compounds for semiconductor and related manufacturing, therefore segment-level operating profit breakdown is not applicable. All revenue and operating profit analysis is conducted at the consolidated level as disclosed in the segment information notes.
[Profitability] ROE of 11.8% (reported, calculated at approximately 15.3% using average equity) exceeds the manufacturing industry median of 6.3% significantly, positioning in the upper quartile. Operating margin of 24.7% substantially outperforms industry median of 7.7% by 17.0pt, demonstrating strong pricing power and operational efficiency in the specialized high-purity chemicals niche. Net profit margin of 17.8% (using Net Income of 42.6B yen divided by revenue) ranks well above industry median of 5.2%. The profitability decomposition shows net margin of 23.1% (using Net Income Attributable to Owners), asset turnover of 0.505x, and financial leverage of 1.31x, with DuPont analysis confirming high margin as the primary ROE driver. Equity method investment income of 12.8B yen represents approximately 23.2% of net income, indicating material reliance on associated company performance. [Cash Quality] Cash and deposits of 72.8B yen provide coverage of 0.96x against short-term liabilities of 76.0B yen, indicating adequate but not excessive liquidity buffer. Operating cash flow of 38.0B yen represents only 0.69x net income coverage, falling below the 0.8x benchmark and signaling earnings quality concerns. Cash conversion efficiency (OCF/EBITDA) of 0.49x is materially below industry standards, driven by working capital expansion. Days Sales Outstanding (DSO) of 68 days exceeds industry median of 73 days modestly but combined with Days Inventory Outstanding (DIO) of 193 days (vs industry median 67 days) results in an extended Cash Conversion Cycle of 211 days, indicating significant working capital inefficiency. [Investment Efficiency] Asset turnover of 0.505x lags industry median of 0.76x by 33.6%, attributable to substantial property, plant and equipment increases to 172.3B yen (up 57.5% YoY) and investment securities rising to 61.4B yen (up 56.5% YoY). Capital expenditure of 62.9B yen against depreciation of 19.2B yen yields a CapEx/D&A ratio of 3.28x, substantially exceeding industry median of 1.08x and indicating aggressive capacity expansion phase. Construction in progress of 9.8B yen (vs 26.8B yen prior year) suggests capital projects are transitioning from construction to operational assets. Return on Invested Capital warrants monitoring as large asset base expansion must translate to proportionate returns. [Financial Health] Equity ratio of 76.5% significantly exceeds industry median of 60.7%, reflecting conservative capital structure. Current ratio of 305.8% (vs industry median 266x) and debt-to-equity ratio of 0.31x demonstrate strong financial stability. Long-term loans increased substantially from 7.2B yen to 30.8B yen (up 326.4%), funding growth investments while maintaining manageable leverage. Interest coverage ratio of approximately 171x (Operating Income/Interest Expense) indicates minimal debt service burden. Net debt to EBITDA of 0.39x compares favorably to industry median of -0.59x, with the company maintaining net debt position due to borrowing increases outpacing cash accumulation.
Operating cash flow of 38.0B yen represents 0.69x of net income, indicating suboptimal cash conversion with operating CF before working capital changes of 59.3B yen being reduced by significant working capital outflows. Inventory increases consumed 18.8B yen, trade receivables absorbed 12.7B yen, while trade payables provided 10.6B yen of funding, netting to substantial working capital drag. Income taxes paid of 21.1B yen align with reported tax expense. Investing cash flow of negative 70.5B yen was dominated by capital expenditures of 62.9B yen for property, plant and equipment, alongside 7.2B yen for subsidiary and affiliate stock purchases, reflecting aggressive capacity expansion to support future growth. The CapEx intensity of 26.3% of revenue and 3.28x depreciation signals a major investment cycle. Financing cash flow provided 10.9B yen, primarily from long-term borrowing proceeds of 30.0B yen offset by debt repayments of 6.5B yen and dividend payments of 11.4B yen, with minimal treasury stock purchases of 2.5M yen. Free cash flow of negative 32.6B yen (Operating CF minus Investing CF) indicates the company is consuming more cash for investments than operations generate, a pattern sustainable only with strong balance sheet reserves or external financing. Cash position decreased 21.6B yen from 94.4B yen to 72.8B yen despite external borrowing, highlighting the magnitude of investment outflows. The current investment phase requires careful monitoring of project ROI and working capital optimization to return to positive free cash flow generation.
Operating income of 59.0B yen versus ordinary income of 70.9B yen shows non-operating net contribution of approximately 11.9B yen, primarily composed of equity method investment gains of 12.8B yen. This equity method income represents 5.4% of revenue and 18.0% of ordinary income, indicating material earnings contribution from associated companies beyond core operations. Financial income components include interest income of 0.1B yen and dividend income of 1.6M yen, both minimal relative to operating scale. Non-operating expenses of 1.6B yen include interest expense of 0.3B yen and other expenses totaling 0.1B yen. The reliance on equity method gains introduces earnings volatility risk tied to associated company performance. Operating cash flow of 38.0B yen falling short of net income signals cash earnings quality concerns, with the gap primarily attributable to working capital expansion including inventory buildup of 18.8B yen. Comprehensive income of 57.0B yen versus net income of 42.6B yen shows a positive 14.4B yen adjustment from other comprehensive income items including FX translation gains of 0.3B yen, securities valuation gains of 0.3B yen, and share of OCI from equity method investments of 1.2B yen. The core operating business demonstrates strong profit generation with 24.7% operating margin, but heavy dependence on non-cash working capital expansion and equity method gains requires scrutiny regarding sustainability and cash realization of reported earnings.
Full-year forecast projects Revenue of 270.0B yen (FY guidance vs FY actual 238.8B yen implies Q4 target of approximately 31.2B yen), Operating Income of 60.0B yen, Ordinary Income of 63.0B yen, and Net Income Attributable to Owners of 46.0B yen. Progress rates against full-year guidance are Revenue 88.4% (above standard 75% for three quarters), Operating Income 98.3% (substantially ahead of pace), Ordinary Income 112.5% (significantly exceeding full-year target), suggesting potential for upward revision or conservative initial guidance. The ordinary income forecast of 63.0B yen represents a YoY decline of 11.1% from current period's 70.9B yen, primarily attributable to anticipated normalization of equity method gains or one-time factors in the current period. Operating income guidance of 60.0B yen implies only 1.7% YoY growth despite 13.1% revenue growth projection, indicating expected margin compression from 24.7% to approximately 22.2%, consistent with observed gross margin pressure trends. EPS forecast of 141.55 yen compares to actual EPS of 169.72 yen, with the forecast implying lower profitability in the final quarter or full-year recalibration. The substantial over-achievement on ordinary income (112.5% progress) versus operating income (98.3% progress) suggests non-operating items, particularly equity method gains, exceeded expectations. Management noted in forecast assumptions that results may vary significantly due to available information and assumptions, with investor briefing materials to be published March 16, 2026, which should provide clarity on investment project timelines and return expectations given the elevated CapEx environment.
Annual dividend of 35 yen per share (year-end dividend, no interim dividend declared with Q2 DPS of 0 yen) represents a payout ratio of 22.9% based on reported metrics, maintaining a conservative return policy. The dividend of 35 yen per share on approximately 32.5 million shares outstanding implies total dividend payment of approximately 11.4B yen, consistent with cash flow statement disclosure of dividend payments of 11.4B yen. Prior period showed 0 yen per share dividend per disclosed data, making the current 35 yen dividend a new or resumed policy. The payout ratio of 22.9% falls below both the company's apparent historical practice and manufacturing industry median of 33%, indicating room for potential dividend growth. Share repurchase activity was minimal at 2.5M yen, representing negligible capital return. Total shareholder return ratio combining dividends and buybacks approximates 23% ((11.4B + 0.0025B) / 55.15B net income), substantially below industry norms. Free cash flow of negative 32.6B yen means dividends are not covered by free cash flow (FCF dividend coverage of -2.87x), requiring dividend funding from cash reserves or financing activities. However, with cash and deposits of 72.8B yen and strong operating cash flow of 38.0B yen, dividend sustainability appears secure in the near term despite negative FCF. The conservative payout ratio provides substantial buffer for dividend maintenance even if profitability moderates. Forecast guidance shows 0 yen dividend per share projection, creating uncertainty regarding continuation of the 35 yen payment, possibly indicating one-time special dividend character or forecast data timing issues.
Semiconductor demand cyclicality represents a high-probability, high-impact risk given the company's single-segment focus on high-purity chemicals for semiconductor manufacturing. Revenue expanded 26.3% YoY driven by robust demand from China, Taiwan, and Korea semiconductor customers, but this concentration creates vulnerability to industry downturns, with major customers TOPCO, Air Liquide, and Changxin representing concentrated exposure. Historical semiconductor sector volatility suggests demand could contract sharply in cyclical downturns, directly impacting revenue and capacity utilization of the recently expanded production assets.
Working capital management deterioration poses medium-probability, medium-to-high impact risk evidenced by inventory surge from 1.9B yen to 14.3B yen (632.8% increase) and extended days inventory outstanding of 193 days versus industry median of 67 days. Combined with DSO of 68 days, the cash conversion cycle extended to 211 days, tying up substantial capital and creating inventory obsolescence risk in a technology-dependent industry. The 18.8B yen inventory increase consumed operating cash flow, with finished goods at 14.3B yen potentially facing valuation adjustments if demand softens or product specifications change.
Capital investment execution and return realization represents medium-probability, medium-to-high impact risk given capital expenditures of 62.9B yen (3.28x depreciation, 26.3% of revenue) and long-term debt increase to 30.8B yen financing growth projects. Property, plant and equipment expanded 57.5% to 172.3B yen with construction in progress of 9.8B yen indicating ongoing buildout. Return on invested capital must be monitored as the expanded asset base of 472.7B yen total assets (up from 369.4B yen) requires proportionate profit growth to maintain ROIC. Failure to achieve projected returns would impair financial metrics and potentially strain debt service despite currently comfortable 171x interest coverage. The company's March 16, 2026 investor briefing materials should provide crucial details on expected investment payback periods and capacity utilization projections.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: The company demonstrates exceptional profitability positioning versus manufacturing industry peers. ROE of 11.8% (reported) to 15.3% (calculated on average equity) substantially exceeds industry median of 6.3%, ranking in the top quartile. Operating margin of 24.7% outperforms industry median of 7.7% by 17.0 percentage points, reflecting specialized product positioning and pricing power in high-purity semiconductor chemicals. Net profit margin of 17.8% (using reported net income) significantly exceeds industry median of 5.2%, benefiting from equity method investment income contribution of 12.8B yen. The profitability premium appears sustainable given the technical barriers and customer switching costs inherent in high-purity chemical supply relationships.
Efficiency: Asset turnover of 0.505x lags industry median of 0.76x by 33.6%, driven by substantial fixed asset base of 172.3B yen and investment securities of 61.4B yen following aggressive capacity expansion. This efficiency gap is characteristic of capital-intensive expansion phases, with CapEx/Depreciation ratio of 3.28x far exceeding industry median of 1.08x. Working capital management shows material underperformance with DIO of 193 days versus industry median of 67 days and operating working capital turnover extended versus typical manufacturing operations. Cash conversion ratio of 0.69x falls short of industry median 1.46x, indicating earnings quality concerns requiring operational focus.
Financial Health: Equity ratio of 76.5% substantially exceeds industry median of 60.7%, demonstrating conservative capital structure despite recent debt increases. Current ratio of 305.8% provides strong liquidity versus typical manufacturing companies. The Net Debt/EBITDA of 0.39x compares favorably to industry positions, though the company shifted from net cash to net debt position following growth investments. Financial leverage of 1.31x remains well below industry median of 1.61x, providing capacity for additional borrowing if needed to fund continued expansion.
Growth and Investment: Revenue growth of 26.3% YoY substantially exceeds industry median of 3.7%, positioning in the top decile of manufacturing growth rates and reflecting strong semiconductor demand environment. However, the elevated capital intensity and working capital consumption create cash flow pressure with FCF yield materially below industry norms. The Rule of 40 metric (revenue growth plus profit margin) exceeds 40% comfortably, indicating strong growth-profitability balance despite cash flow dynamics.
※ Industry: Manufacturing sector (243 companies), Comparison: FY2025 fiscal periods, Source: Proprietary analysis
Superior profitability positioning with sustainable competitive advantages: The company achieves operating margins of 24.7% and ROE approaching 15%, substantially exceeding manufacturing industry medians of 7.7% and 6.3% respectively, reflecting defensible market position in specialized high-purity chemicals for semiconductor manufacturing. Customer relationships with major semiconductor manufacturers (TOPCO, Air Liquide, Changxin) and technical barriers to entry in ultra-high purity production create pricing power and profitability moats. Equity method investment income of 12.8B yen contributing 18% of ordinary income provides additional earnings diversification, though with associated volatility risk. The margin premium has persisted despite 26.3% revenue growth, suggesting pricing power rather than temporary capacity constraints driving profitability.
Aggressive growth investment phase creating near-term cash consumption but potential long-term capacity: Capital expenditures of 62.9B yen representing 3.28x depreciation and 26.3% of revenue, alongside long-term debt increases from 7.2B to 30.8B yen, fund substantial capacity expansion to capture semiconductor industry growth. Property, plant and equipment expanded 57.5% to 172.3B yen with construction in progress of 9.8B yen indicating ongoing buildout, positioning for anticipated demand increases in high-purity chemicals. However, this investment cycle produces negative free cash flow of 32.6B yen and asset turnover deterioration to 0.505x (vs industry median 0.76x), requiring successful volume ramp and utilization improvements to generate acceptable returns on the expanded asset base. The March 16, 2026 investor briefing should provide critical visibility into expected investment payback periods and capacity utilization trajectories.
Working capital efficiency deterioration represents material operational and cash flow risk requiring remediation: Inventory ballooned from 1.9B to 14.3B yen (632.8% increase) with days inventory outstanding of 193 days versus industry median of 67 days, while trade receivables rose 35.8% to 44.4B yen extending the cash conversion cycle to 211 days. This working capital expansion consumed 21.3B yen of operating cash flow (inventory increase of 18.8B yen plus receivables increase of 12.7B yen net of payables), reducing cash conversion ratio to 0.69x versus industry median of 1.46x. The inventory accumulation may reflect production ramp-up for new capacity, but creates obsolescence risk in technology-dependent markets and impairs cash generation quality. Operating cash flow of 38.0B yen representing only 0.69x net income coverage signals earnings quality concerns, with management focus on working capital optimization critical to return to sustainable free cash flow generation and validate the reported strong profitability metrics.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.